Enhancement of the lower extremities computed tomography: Iomeron®-400 vs. Visipaque™-320 (Electiv) - ELECTIV

Bracco Imaging S.p.A.0 个研究点目标入组 120 人开始时间: 2005年5月26日最近更新: 2013年7月15日

适应症

试验速览

暂无简介。

•Provide written Informed Consent and are willing to comply with protocol requirements
•18 years of age or older,
•Have a stable* baseline serum creatinine level of SCr=1.5-2.5 mg/dL and/or calculated CrCl = 10-60 mL/min.
•*2 stable values: one within 6 months and one within 2 weeks before the examination,
•Referred for a clinically-indicated contrast-enhanced MDCTA examination of the lower extremity arterial system.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Determined, by their physicians, that prophylactic medication is medically required for them to receive intravascular administration of an iodinated contrast agent,
•A history of hypersensitivity to iodine-containing compounds,
•Severe congestive heart failure (class III-IV NYHA),
•Suspicion of hyperthyroidism or thyroid malignancies,
•Undergone any other radiological procedure utilizing x-ray contrast media from 72 hours before to 7 days after the administration of the study agent,
•Uncontrolled diabetes,
•Unstable renal function/ serum creatinine levels/ acute renal failure,
•Is a pregnant or lactating female. Exclude the possibility of pregnancy:
•-by testing on site at the institution (serum or urine ßHCG) within 24 hours prior to the start of study agent administration
•-by history (eg, tubal ligation or hysterectomy)
•-post menopausal with a minimum 1 year without menses
•(time of pregnancy test in relation to study agent administration must be recorded);
•Previously entered in this study or having received an investigational drug within 30 days prior to admission to this study,
•Any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data or achieving the study objectives, i.e.:
•-drug dependence,
•-psychiatric disorders, dementia, or other reasons for expected poor compliance with investigator’s instructions

发起方